Latisse Appeal, Scottish Web: Intellectual Property

Sept. 15 (Bloomberg) -- Allergan Inc. and Duke University won’t have their patent suit for the Latisse eyelash drug reheard by the U.S. Court of Appeals for the Federal Circuit.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.